Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • fasinumab

    - PMLiVE

    Regeneron’s Libtayo receives EC approval for skin cancer

    Phase 3 trial results showed the drug significantly improved disease-free survival

    - PMLiVE

    Sanofi/Regeneron’s Dupixent granted FDA approval for bullous pemphigoid

    Around 27,000 adults in the US are living with uncontrolled cases of the chronic skin disease

    - PMLiVE

    Sanofi/Regeneron share results for Dupixent in atopic dermatitis patients with darker skin tones

    These are the first clinical study results for the drug in a large population of patients with darker skin tones

    regeneron headquarters

    Regeneron’s bispecific antibody Lynozyfic approved by EC to treat multiple myeloma

    More than 35,000 new cases of the blood cancer are diagnosed in Europe every year

    - PMLiVE

    Sanofi/Regeneron’s Dupixent granted FDA approval for chronic spontaneous urticaria

    More than 300,000 people in the US are living with uncontrolled cases of the inflammatory skin disease

    - PMLiVE

    Sanofi and Regeneron’s Dupixent granted FDA priority review for bullous pemphigoid

    Approximately 27,000 adults in the US are living with uncontrolled cases of the skin disease

    regeneron headquarters

    Regeneron shares positive late-stage results for poze-cemdi in rare blood disorder PNH

    Paroxysmal nocturnal haemoglobinuria affects up to 1.5 people per million in the US

    - PMLiVE

    Sanofi/Regeneron’s Dupixent approved by EC for younger eosinophilic oesophagitis patients

    Dupixent is now the first drug in the EU indicated for use in this patient population

    - PMLiVE

    Sanofi/Regeneron’s Dupixent approved by FDA to treat uncontrolled COPD

    Approximately 300,000 patients in the US will be eligible for the therapy

    - PMLiVE

    Sanofi/Regeneron’s Dupixent recommended by CHMP for younger eosinophilic oesophagitis patients

    If approved, Dupixent would be the first drug in the EU indicated for this patient population

    - PMLiVE

    Sanofi/Regeneron’s Dupixent receives FDA approval for adolescents with CRSwNP

    Approximately 9,000 adolescents in the US are living with inadequately controlled cases of the chronic disease

    - PMLiVE

    Sanofi/Regeneron’s Dupixent approved by MHRA to treat uncontrolled COPD

    Approximately 1.4 million people in the UK have been diagnosed with the respiratory disease

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links